Compare MORN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | JAZZ |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.4B |
| IPO Year | 2004 | 2007 |
| Metric | MORN | JAZZ |
|---|---|---|
| Price | $183.50 | $201.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $256.50 | $217.57 |
| AVG Volume (30 Days) | 431.2K | ★ 835.2K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 3.38 | N/A |
| EPS | ★ 8.87 | N/A |
| Revenue | ★ $2,445,500,000.00 | $1,618,693,000.00 |
| Revenue This Year | $9.14 | $6.22 |
| Revenue Next Year | $7.23 | $7.68 |
| P/E Ratio | $20.06 | ★ N/A |
| Revenue Growth | ★ 7.49 | N/A |
| 52 Week Low | $149.08 | $105.00 |
| 52 Week High | $316.71 | $207.48 |
| Indicator | MORN | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 60.13 |
| Support Level | $178.51 | $159.78 |
| Resistance Level | $190.99 | $207.48 |
| Average True Range (ATR) | 6.19 | 5.38 |
| MACD | 0.50 | -0.24 |
| Stochastic Oscillator | 65.21 | 61.81 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.